Physiomics plc combines systems biology with cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the company’s lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical trials. This optimisation improves the efficacy of combinations in pre-clinical xenografts.
The company is also developing:
- Virtual Tumour Clinical, to directly predict optimal regimens for human clinical trials.
- Cardiac tox prediction service, to predict unwanted toxic side effects of drug candidates early on in the drug discovery process.
- Drug combinations database, for researchers and clinicians to rapidly access literature data on pre-clinical and clinical regimens and their effects.
Physiomics has worked with Eli Lilly since 2007 and recently added a further large pharmaceutical client. In addition, Physiomics has collaborated with a number of other companies including Bayer Technology Services, Sareum, ValiRx, Cancer Research Technologies and Cyclacel. Fee-for-service, licensing and revenue sharing options are available.
Dr Mark Chadwick
Mr Peter RidgwayBusiness Development Director
Mr Simon BuryBusiness Development Director - Discovery
UK BioIndustry Association (BIA)
Founded over 20 years ago at the infancy of biotechnology, the BIA is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.